Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| AMNEAL PHARMACEUTICALS | 8 | - | +3,60 % | ||
| BIONTECH | 7 | 13 | -2,31 % | ||
| MEDPACE | 6 | - | -1,55 % | ||
| INHIBRX BIOSCIENCES | 5 | - | 0,00 % | ||
| REGENERON PHARMACEUTICALS | 4 | 22 | -0,64 % | ||
| MAZE THERAPEUTICS | 4 | - | +3,27 % | ||
| AMGEN | 3 | 27 | +0,26 % | ||
| MODERNA | 3 | 16 | +2,40 % | ||
| HUMACYTE | 3 | 4 | 0,00 % | ||
| VANDA PHARMACEUTICALS | 3 | - | +1,47 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:34 | Medpace (MEDP) Q1 Earnings and Revenues Beat Estimates | 2 | Zacks | ||
| 00:29 | Medpace Holdings, Inc. Bottom Line Rises In Q1 | 1 | RTTNews | ||
| Mi | Medpace falls despite Q1 beats; 2026 guidance ranges include consensus | 1 | Seeking Alpha | ||
| Mi | FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral | 3 | MedCity News | ||
| Mi | Vanda Pharmaceuticals adds Charles Duncan to board | 1 | Investing.com | ||
| Mi | Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) | 3 | GlobeNewswire (USA) | ||
| Mi | Sanofi: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria | 238 | GlobeNewswire (Europe) | Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Approval for children aged two to 11 years with... ► Artikel lesen | |
| Mi | Vanda Pharmaceuticals erweitert Verwaltungsrat um Charles Duncan | 2 | Investing.com Deutsch | ||
| Mi | Neurocrine meldet anhaltende Glukokortikoid-Reduktion in CAH-Studie | 6 | Investing.com Deutsch | ||
| Mi | Altimmune launches proposed public offering to fund late-stage trial | 3 | Seeking Alpha | ||
| Mi | Definium expects three trial readouts for depression, anxiety drug | 2 | Investing.com | ||
| Mi | Altimmune, Inc: Altimmune Announces Proposed Underwritten Public Offering of Securities | 3 | GlobeNewswire (USA) | ||
| Mi | Vanda Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| Mi | Neurocrine reports sustained glucocorticoid reductions in CAH study | 1 | Investing.com | ||
| Mi | Medpace GAAP EPS of $4.28 beats by $0.40, revenue of $706.6M beats by $8.97M | 3 | Seeking Alpha | ||
| Mi | Lifecore Biomedical, Inc.: Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Mi | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | 221 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| Mi | Alpha Teknova, Inc.: Teknova to Report First Quarter 2026 Financial Results on May 6, 2026 | 1 | GlobeNewswire (USA) | ||
| Mi | Raymond James bestätigt "Outperform"-Rating für Regeneron mit Kursziel von 910 US-Dollar | 3 | Investing.com Deutsch | ||
| Mi | Maze Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.